Sigrun Chrubasik-Hausmann1, Julia Vlachojannis1, Andrew J McLachlan2,3. 1. Institute of Forensic Medicine, University of Freiburg, Freiburg, Germany. 2. Centre for Education and Research on Ageing, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, Australia. 3. Concord Repatriation General Hospital, Sydney, NSW, Australia.
Abstract
OBJECTIVE: The aim of this study was to review herb-drug interaction studies with St John's wort (Hypericum perforatum L.) with a focus on the hyperforin content of the extracts used in these studies. METHODS: PUBMED was systematically searched to identify studies describing pharmacokinetic interactions involving St John's wort. Data on study design and the St John's wort extract or product were gathered to extract hyperforin content and daily dose used in interaction studies. KEY FINDINGS: This analysis demonstrates that significant herb-drug interactions (resulting in a substantial change in systemic exposure) with St John's wort products were associated with hyperforin daily dosage. Products that had a daily dose of <1 mg hyperforin were less likely to be associated with major interaction for drugs that were CYP3A4 or p-glycoprotein substrates. Although a risk of interactions cannot be excluded even for low-dose hyperforin St. John's wort extracts, the use of products that result in a dose of not more than 1 mg hyperforin per day is recommended to minimise the risk of interactions. CONCLUSIONS: This review highlights that the significance of herb-drug interactions with St John's wort is influenced by the nature of the herbal medicines product, particularly the hyperforin content.
OBJECTIVE: The aim of this study was to review herb-drug interaction studies with St John's wort (Hypericum perforatum L.) with a focus on the hyperforin content of the extracts used in these studies. METHODS: PUBMED was systematically searched to identify studies describing pharmacokinetic interactions involving St John's wort. Data on study design and the St John's wort extract or product were gathered to extract hyperforin content and daily dose used in interaction studies. KEY FINDINGS: This analysis demonstrates that significant herb-drug interactions (resulting in a substantial change in systemic exposure) with St John's wort products were associated with hyperforin daily dosage. Products that had a daily dose of <1 mg hyperforin were less likely to be associated with major interaction for drugs that were CYP3A4 or p-glycoprotein substrates. Although a risk of interactions cannot be excluded even for low-dose hyperforin St. John's wort extracts, the use of products that result in a dose of not more than 1 mg hyperforin per day is recommended to minimise the risk of interactions. CONCLUSIONS: This review highlights that the significance of herb-drug interactions with St John's wort is influenced by the nature of the herbal medicines product, particularly the hyperforin content.
Authors: Jennifer L Wilson; Kit Wun Kathy Cheung; Lawrence Lin; Elizabeth A E Green; Analia I Porrás; Ling Zou; David Mukanga; Paul A Akpa; Delese Mimi Darko; Rae Yuan; Sheng Ding; Wiltshire C N Johnson; Howard A Lee; Emer Cooke; Carl C Peck; Steven E Kern; Dan Hartman; Yoshikazu Hayashi; Peter W Marks; Russ B Altman; Murray M Lumpkin; Kathleen M Giacomini; Terrence F Blaschke Journal: Sci Transl Med Date: 2020-07-29 Impact factor: 17.956
Authors: Irina-Iuliana Costache; Anca Miron; Monica Hăncianu; Viviana Aursulesei; Alexandru Dan Costache; Ana Clara Aprotosoaie Journal: Cardiovasc Ther Date: 2019-09-02 Impact factor: 3.023